Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00997230
Other study ID # NIS-ODE-DUM-2009/1
Secondary ID
Status Completed
Phase N/A
First received October 16, 2009
Last updated October 25, 2013
Start date September 2009
Est. completion date October 2012

Study information

Verified date October 2013
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Observational

Clinical Trial Summary

The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological characteristics (e.g. smoking status, sex, histology, etc). In particular, the study will aim to determine the frequency of EGFR M+ lung cancers in patients with clinico-pathological characteristics that are not commonly associated with EGFR mutation positivity (i.e., smokers, men, and non-adenocarcinoma).


Description:

An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cancer)


Recruitment information / eligibility

Status Completed
Enrollment 4243
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV). Mixed histology of small cell and non-small cell lung cancer

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Research Site Aachen
Germany Research Site Amberg
Germany Research Site Ansbach
Germany Research Site Aschaffenburg
Germany Research Site Augsburg
Germany Research Site Bad Berka
Germany Research Site Ballenstedt
Germany Research Site Bamberg
Germany Research Site Bayreuth
Germany Research Site Berlin
Germany Research Site Bielefeld
Germany Research Site Bitterfeld-Wolfen
Germany Research Site Bochum
Germany Research Site Bonn
Germany Research Site Borstel
Germany Research Site Bottrop
Germany Research Site Braunschweig
Germany Research Site Bremen
Germany Research Site Bremerhaven
Germany Research Site Celle
Germany Research Site Chemnitz
Germany Research Site Coswig
Germany Research Site Cottbus
Germany Research Site Darmstadt
Germany Research Site Deggendorf
Germany Research Site Dessau-Rosslau
Germany Research Site Donaustauf
Germany Research Site Dortmund
Germany Research Site Dresden
Germany Research Site Dusseldorf
Germany Research Site Eisenach
Germany Research Site Erlangen
Germany Research Site Essen
Germany Research Site Esslingen
Germany Research Site Flensburg
Germany Research Site Frankfurt
Germany Research Site Freiburg
Germany Research Site Freising
Germany Research Site Fulda
Germany Research Site Gerlingen
Germany Research Site Gieben
Germany Research Site Goslar
Germany Research Site Gottingen
Germany Research Site Greifenstein
Germany Research Site Grobhansdorf
Germany Research Site Halle
Germany Research Site Halle-Dolau
Germany Research Site Hamburg
Germany Research Site Hamm
Germany Research Site Hannover
Germany Research Site Heidelberg
Germany Research Site Hemer
Germany Research Site Hof
Germany Research Site Homburg
Germany Research Site Immenhausen
Germany Research Site Jena
Germany Research Site Karlsruhe
Germany Research Site Kassel
Germany Research Site Kiel
Germany Research Site Koblenz
Germany Research Site Koln
Germany Research Site Landshut
Germany Research Site Leipzig
Germany Research Site Lemgo
Germany Research Site Leverkusen
Germany Research Site Lostau
Germany Research Site Lowenstein
Germany Research Site Lubeck
Germany Research Site Ludwigshafen
Germany Research Site Luneburg
Germany Research Site Lunen
Germany Research Site Magdeburg
Germany Research Site Mainz
Germany Research Site Mannheim
Germany Research Site Marburg
Germany Research Site Minden
Germany Research Site Moers
Germany Research Site Mulheim
Germany Research Site Munchen
Germany Research Site Munnerstadt
Germany Research Site Munster
Germany Research Site Neuss
Germany Research Site Nordhausen
Germany Research Site Northeim
Germany Research Site Nurnberg
Germany Research Site Oberhausen
Germany Research Site Offenbach
Germany Research Site Offenburg
Germany Research Site Oldenburg
Germany Research Site Osnabruck
Germany Research Site Ostfildern
Germany Research Site Paderborn
Germany Research Site Passau
Germany Research Site Querfurt
Germany Research Site Recklinghausen
Germany Research Site Regensburg
Germany Research Site Rosenheim
Germany Research Site Rostock
Germany Research Site Saarbrucken
Germany Research Site Schonebeck
Germany Research Site Solingen
Germany Research Site Sonneberg
Germany Research Site Stralsund
Germany Research Site Stuttgart
Germany Research Site Suhl
Germany Research Site Treuenbrietzen
Germany Research Site Trier
Germany Research Site Tubingen
Germany Research Site Ulm
Germany Research Site Velbert
Germany Research Site Villingen-Schwenningen
Germany Research Site Volklingen
Germany Research Site Wangen/Allgau
Germany Research Site Weiden
Germany Research Site Wiesbaden
Germany Research Site Wurselen
Germany Research Site Wurzburg
Germany Research Site Zusmarshausen

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological characteristics Days 1-10 No
Secondary To collect real-life clinical outcome data in all EGFR M+ patients up to and including progression.To collect real-life pharmacoeconomic data (resource use) associated with the diagnosis and treatment of EGFR M+ patients. Study Days 21-30 No